Capital Impact Advisors, LLC Blueprint Medicines Corp Transaction History

Capital Impact Advisors, LLC

  • $3.16 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$42.2 - $66.37 $23,210 - $36,503
550 Added 5.43%
10,676 $674,000
Q1 2023

May 23, 2023
BUY
$37.97 - $50.0 $106,353 - $140,050
2,801 Added 38.24%
10,126 $455,000
Q3 2022

Nov 21, 2022
BUY
$49.93 - $77.7 $65,907 - $102,564
1,320 Added 21.98%
7,325 $312,000
Q2 2022

Aug 15, 2022
SELL
$45.23 - $70.15 $108,823 - $168,780
-2,406 Reduced 28.61%
6,005 $303,000
Q1 2022

May 16, 2022
BUY
$54.1 - $110.08 $40,250 - $81,899
744 Added 9.7%
8,411 $537,000
Q4 2021

Feb 14, 2022
BUY
$94.25 - $115.99 $722,614 - $889,295
7,667 New
7,667 $821,000

Others Institutions Holding BPMC

# of Institutions
379
Shares Held
61.6M
Call Options Held
1.6M
Put Options Held
1.41M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.69B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Capital Impact Advisors, LLC Portfolio

Follow Capital Impact Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Impact Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email